Metadata record for the article: Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial

Summary

This
metadata record provides details of the data supporting the claims of the
related article: “Effect of Metformin versus Placebo on
Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial”.

The
related study examined metformin impact on metabolic factors in non-diabetic
subjects to determine whether this impact varies by baseline BMI, insulin and
rs11212617 SNP in CCTG MA.32, a double-blind placebo controlled randomised
adjuvant breast cancer (BC) trial.

Type of data:
single-nucleotide polymorphism (SNP); clinical data

Subject of
data: Homo sapiens

Sample size:
2915

Population
characteristics: See Table 1 of the related article

Trial
registration number: http://clinicaltrials.gov/show/NCT01101438

Data
access

The SNP data
are openly available as part of this figshare
metadata record in the file ‘MA32_snp_data.csv’.

The primary
efficacy analysis will be available from the Canadian Cancer Trials Group
(Kingston, Ontario) after the results of the analysis have been published. These
data will be uploaded to the NCI data archive website: https://nctn-data-archive.nci.nih.gov/view-trials
and will be searchable via NCT trial number
NCT01101438. As of April 2021, the group is working towards this
publication. Further details can be requested from the corresponding author.

The clinical
data are not publicly available for the following reason: data contain information that could compromise research
participant privacy.

Corresponding author(s) for this study

Dr.
Pamela J. Goodwin, Mount Sinai Hospital, 1085-600 University Avenue, Toronto,
Ontario M5G 1X4. Tel: [phone]. Fax: [phone]. Email:
[e-mail].

Study approval

The
study protocol was approved by institutional review boards of participating
institutions, including the NCI (US) Central Institutional Review Board and
Mount Sinai Hospital (Ontario Cancer Research Ethics Board).